ClinicalTrials.gg
Not yet recruitingNCT07528898Updated Apr 14, 2026

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

A Phase 2 interventional study of SHR-A1811 and Pertuzumab in Breast Cancer, sponsored by Hebei Medical University Fourth Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Hebei Medical University Fourth Hospital · Phase 2, Interventional, and Treatment

How we know · 9 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies testing trastuzumab rezetecan in Breast Neoplasms — 46 open to participants now, 52 under way, 10 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
28th of 53
100 · median 111
Started
2026
with 20 others
Phase 2
34 of 53
34 open now
Primary completion
2027-07
later than 20 of 51 live
Registered
41st of 53
by date

Among the 53 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 28th largest by planned enrollment, is one of 21 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 20 of the 51 other live ones, and was the 41st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

46 of the 53 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

41 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, two-arm, exploratory clinical study designed to evaluate the efficacy and safety of a response-guided neoadjuvant treatment strategy in patients with HER2-positive early or locally advanced breast cancer.

Breast cancer is the most common malignancy in women worldwide, and HER2-positive disease accounts for approximately 15-20% of cases and is associated with aggressive tumor biology and a higher risk of recurrence. The introduction of HER2-targeted therapies, including trastuzumab and pertuzumab, has significantly improved patient outcomes. However, a proportion of patients exhibit suboptimal response to standard neoadjuvant therapy, highlighting the need for more effective treatment strategies.

In this study, approximately 100 eligible patients will be enrolled. All patients will initially receive 2 cycles of standard neoadjuvant therapy with trastuzumab, pertuzumab, and chemotherapy (THP or TCbHP). Tumor response will be assessed according to RECIST version 1.1 criteria. Patients with tumor reduction greater than 40% will continue the same regimen for an additional 4 cycles. Patients with tumor reduction of 40% or less will switch to an alternative regimen consisting of SHR-A1811, a novel HER2-targeted antibody-drug conjugate, in combination with pertuzumab for 4 cycles.

SHR-A1811 is an investigational HER2-targeted antibody-drug conjugate designed to deliver a cytotoxic payload directly to tumor cells, potentially overcoming resistance to prior HER2-targeted therapies. Emerging clinical data have demonstrated promising anti-tumor activity and manageable safety in HER2-positive breast cancer.

Clinical data, including baseline characteristics, imaging findings, and pathological markers such as Ki-67, will be collected throughout the study. Efficacy will be evaluated based on imaging assessments according to RECIST 1.1 criteria and pathological response at surgery, while safety will be monitored during treatment.

The primary objective of this study is to explore whether switching to SHR-A1811 in combination with pertuzumab in patients with suboptimal early response can improve pathological complete response (pCR) rates. Secondary objectives include evaluation of safety and tolerability of the treatment strategies.

This study aims to provide evidence for an individualized, response-adapted neoadjuvant treatment approach in HER2-positive breast cancer, and to optimize treatment outcomes for patients with inadequate response to standard therapy.

Read the detailed description

HER2-positive breast cancer is driven by overexpression or amplification of the HER2 receptor, leading to activation of downstream signaling pathways such as MAPK and PI3K/AKT that promote tumor growth and survival. Although dual HER2 blockade with trastuzumab and pertuzumab in combination with chemotherapy has become a standard neoadjuvant treatment, a subset of patients exhibit insufficient tumor response, indicating biological heterogeneity and potential resistance to therapy.

Pathological complete response (pCR) after neoadjuvant treatment is associated with improved long-term outcomes in HER2-positive breast cancer. Therefore, early identification of patients with suboptimal response and timely treatment modification may represent an effective strategy to improve prognosis.

Antibody-drug conjugates (ADCs) are designed to selectively deliver cytotoxic agents to tumor cells through antigen-specific targeting. SHR-A1811 is an investigational HER2-directed ADC composed of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload via a cleavable linker. Preclinical data have demonstrated potent anti-tumor activity in HER2-expressing models, including those with reduced sensitivity to prior HER2-targeted therapies.

Emerging clinical evidence supports the antitumor activity and manageable safety profile of SHR-A1811 in HER2-positive breast cancer. Its mechanism of action suggests potential benefit in patients with inadequate response to standard HER2-targeted neoadjuvant regimens.

This study is designed to investigate a response-adapted treatment strategy, in which early tumor response is used to guide subsequent therapy selection. By incorporating an alternative HER2-targeted approach for patients with suboptimal response, this study aims to explore strategies to improve treatment efficacy while maintaining an acceptable safety profile.

The results of this study are expected to provide evidence to support individualized neoadjuvant treatment strategies for patients with HER2-positive breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • HER2-positive
  • Neoadjuvant therapy
  • Antibody-drug conjugate
  • SHR-A1811
  • HER2-targeted therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

  1. Age ≥18 and ≤70 years.
  2. (ECOG) performance status of 0-1.
  3. At least one according to version 1.1.
  4. confirmed invasive breast cancer with clinical stage:

Stage II (T2N0-1M0 or T3N0M0), or Stage III (T2N2-3M0, T3N1-3M0, or T4N0-3M0). 5.-positive invasive breast cancer confirmed by histopathology, defined as: HER2 immunohistochemistry (IHC) 3+, or HER2 IHC 2+ with fluorescence in situ hybridization (FISH) positivity, as determined by the pathology department of the participating center. 6.Adequate organ function, defined as:

  1. Hematologic function (no blood transfusion, blood products, granulocyte colony-stimulating factor [G-CSF], or other hematopoietic growth factors within 14 days prior to testing):

    (Hb) ≥100 g/L; (ANC) ≥1.5 × 10⁹/L; count (PLT) ≥100 × 10⁹/L.

  2. Biochemical function:

    Total (TBIL) ≤1 × (ULN); (ALT) and aspartate aminotransferase (AST) ≤1.5 × ULN; Alkaline phosphatase (ALP) ≤2.5 × ULN; Blood urea nitrogen (BUN) and serum creatinine (Cr) ≤1.5 × ULN.

  3. Cardiac function:

(LVEF) ≥55% by echocardiography; corrected by Fridericia's formula (QTcF) ≤450 ms. 7.Women of must have a negative serum pregnancy test within 14 days prior to enrollment and agree to use effective during the study and for at least 8 weeks after the last dose of study treatment.

8.Willingness to participate in the study, provide written , and comply with study procedures and follow-up.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

  1. Prior receipt of any anti-tumor therapy not specified in the study protocol, including but not limited to chemotherapy, radiotherapy, targeted therapy, or endocrine therapy for the current breast cancer.
  2. Concurrent receipt of any other anti-tumor therapy during the study. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer. Stage IV () breast cancer.
  3. History of other within the past 5 years, except for adequately treated carcinoma in situ of the cervix.
  4. Severe dysfunction of major organs, including but not limited to cardiac, hepatic, or renal insufficiency.
  5. Participation in another interventional clinical trial within 4 weeks prior to enrollment.
  6. Known to any component of the study drugs; history of immunodeficiency, including positive (HIV) test, active virus (HCV) infection, active infection, congenital or acquired immunodeficiency disorders, or history of organ transplantation.

    History of significant cardiac disease, including but not limited to:

    arrhythmia requiring treatment; Myocardial infarction; Heart failure;

  7. Any other cardiac condition that, in the investigator's judgment, makes the participant unsuitable for the study.
  8. Pregnant or breastfeeding women; women of with a positive pregnancy test at baseline or unwilling to use effective throughout the study period.
  9. Any serious concomitant disease that, in the investigator's judgment, may compromise patient safety or interfere with study participation, including but not limited to uncontrolled hypertension, severe diabetes, or active infection.

    History of neurological or psychiatric disorders, including epilepsy or dementia.

  10. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Standard Neoadjuvant Therapy (THP/TCbHP)

    All enrolled patients will initially receive 2 cycles of standard neoadjuvant therapy with trastuzumab, pertuzumab, and chemotherapy (THP or TCbHP). Patients who achieve a tumor reduction greater than 40% according to RECIST version 1.1 will continue the same regimen for an additional 4 cycles.

    Drug: Pertuzumab · Drug: trastuzumab · Drug: Chemotherapy

  • Experimental
    SHR-A1811 Plus Pertuzumab

    All enrolled patients will initially receive 2 cycles of standard neoadjuvant therapy. Patients with a tumor reduction of 40% or less according to RECIST version 1.1 will switch to SHR-A1811 in combination with pertuzumab for 4 cycles.

    Drug: SHR-A1811 · Drug: Pertuzumab

Interventions

  • DrugTrastuzumab rezetecanStudies of Trastuzumab rezetecanTrastuzumab rezetecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SHR-A1811 is a HER2-targeted antibody-drug conjugate administered intravenously in combination with pertuzumab as neoadjuvant therapy.

  • Pertuzumab is a monoclonal antibody targeting HER2, administered intravenously as part of dual HER2 blockade.

  • Trastuzumab is a HER2-targeted monoclonal antibody administered intravenously as part of standard neoadjuvant therapy.

  • DrugChemotherapy

    Chemotherapy includes taxane-based regimens with or without carboplatin (THP or TCbHP) administered according to institutional standards.

06

What researchers measure

Primary outcomes

  1. Total Pathological Complete Response (tpCR)

    Number of participants achieving total pathological complete response, defined as no residual invasive cancer in both breast and axillary lymph nodes (ypT0/is ypN0) at the time of surgery following completion of neoadjuvant therapy.Metric:Proportion of participants (%)

    Time frame: At surgery (approximately 18 weeks after initiation of treatment)

Secondary outcomes

  1. Objective Response Rate (ORR) per RECIST v1.1

    Proportion of participants with a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1.

    Time frame: From baseline to surgery (approximately 18 weeks)

  2. Event-Free Survival (EFS)

    Time from treatment initiation to the occurrence of disease progression, local or distant recurrence, or death from any cause.Metric:Time-to-event (months).

    Time frame: From first dose up to 3 years

  3. Breast Conservation Rate

    Proportion of participants who undergo breast-conserving surgery after completion of neoadjuvant therapy.

    Time frame: At surgery (approximately 18 weeks)

  4. Number of Participants With Treatment-Related Adverse Events (TRAEs)

    Number of participants experiencing treatment-related adverse events, assessed according to CTCAE version 5.0.

    Time frame: From first dose to 30 days after last dose

  5. Number of Participants With Grade ≥3 Adverse Events

    Number of participants experiencing Grade 3 or higher adverse events according to CTCAE version 5.0.

    Time frame: From first dose to 30 days after last dose

  6. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants experiencing serious adverse events as defined by ICH guidelines.

    Time frame: From first dose to 30 days after last dose

Other outcomes

  1. Change in Circulating Tumor DNA (ctDNA) Levels

    Change in ctDNA levels from baseline to post-treatment timepoints (after 2 cycles and pre-surgery), measured using next-generation sequencing.

    Time frame: Baseline, after 2 cycles (~6 weeks), and pre-surgery (~18 weeks)

  2. Predictive Performance of Multi-modal Biomarker Model for Treatment Response

    Evaluation of a predictive model integrating genomic features, clinicopathological characteristics, imaging findings, and laboratory biomarkers to predict pathological response.Metric:Area under the curve (AUC).

    Time frame: Up to surgery (~18 weeks)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this study, after de-identification, will be made available upon reasonable request. The study protocol, statistical analysis plan, and informed consent form may also be available. Data will be available beginning 6 months after publication and ending 3 years after publication. Requests should be directed to the corresponding author or sponsor.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jul 2027, 14 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 14 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 14, 2026
StartEst.
May 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2029
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07528898
Lead sponsor
Hebei Medical University Fourth Hospital
Responsible party
Li Ma (Chief Physician, Breast Center, Hebei Medical University Fourth Hospital) — Principal investigator
First posted
Apr 14, 2026
Start date
May 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2029 (estimated)
Last update
Apr 14, 2026

Study contacts

Li Ma, MD
Contact
mali1021@126.com
13932116886

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion